GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » Operating Cash Flow per Share

Boiron (FRA:BON) Operating Cash Flow per Share : €2.62 (TTM As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Boiron Operating Cash Flow per Share?

Boiron's operating cash flow per share for the six months ended in Dec. 2023 was €1.68. Boiron's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was €2.62.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Boiron was -22.40% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -12.40% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -8.80% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -8.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Boiron's Operating Cash Flow per Share or its related term are showing as below:

FRA:BON' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -26.2   Med: 3.1   Max: 31.8
Current: -12.4

During the past 13 years, Boiron's highest 3-Year average Operating Cash Flow per Share Growth Rate was 31.80% per year. The lowest was -26.20% per year. And the median was 3.10% per year.

FRA:BON's 3-Year OCF Growth Rate is ranked worse than
74.94% of 806 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs FRA:BON: -12.40

Boiron Operating Cash Flow per Share Historical Data

The historical data trend for Boiron's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boiron Operating Cash Flow per Share Chart

Boiron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.90 3.90 1.90 3.38 2.62

Boiron Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 2.37 1.01 0.95 1.68

Competitive Comparison of Boiron's Operating Cash Flow per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boiron's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Boiron's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Boiron's Price-to-Operating-Cash-Flow falls into.



Boiron Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Boiron's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=45.491/17.362
=2.62

Boiron's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )=Cash Flow from Operations (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=29.09/17.362
=1.68

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boiron Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Boiron's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Boiron (FRA:BON) Business Description

Industry
Traded in Other Exchanges
Address
2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510
Boiron is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.